Sarcopenia and cardiovascular disease in patients with and without kidney disease: what do we know?

被引:0
|
作者
Ozkan Gungor
Mustafa Sevinc
Sena Ulu
Ismail Kocyigit
机构
[1] Kahramanmaras Sutcu Imam University,Nephrology Department, Medical Faculty
[2] Bakirkoy Dr. Sadi Konuk Education and Research Hospital,Nephrology Department
[3] Bahcesehir University,Nephrology Department, Medical Faculty
[4] Erciyes University,Nephrology Department, Medical Faculty
来源
International Urology and Nephrology | 2023年 / 55卷
关键词
Sarcopenia; Cardiovascular disease; Kidney patients; Muscle; Kidney;
D O I
暂无
中图分类号
学科分类号
摘要
Cardiovascular disease (CVD) incidence is high in patients with chronic kidney disease (CKD) and is the most frequent cause of mortality in this population. Advanced age, hypertension, uremic toxins, endothelial dysfunction, atherosclerosis, hyperhomocysteinemia, oxidative stress, and inflammation are among the leading causes of increased CVD in advanced stages of CKD. Although defined as a decrease in muscle strength associated with aging, sarcopenia is also prevalent in CKD patients. Sarcopenia causes physical disability, low quality of life, and mortality. Regular exercise and nutritional supplementation may slow the progression of sarcopenia. Recent studies have shown that sarcopenia increases the risk of CVD and mortality in people with or without kidney disease. This review discusses the relationship between sarcopenia and CVD in light of the current literature.
引用
收藏
页码:1161 / 1171
页数:10
相关论文
共 50 条
  • [1] Sarcopenia and cardiovascular disease in patients with and without kidney disease: what do we know?
    Gungor, Ozkan
    Sevinc, Mustafa
    Ulu, Sena
    Kocyigit, Ismail
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2023, 55 (05) : 1161 - 1171
  • [2] NETosis and kidney disease: what do we know?
    Demet Alaygut
    Ilyas Ozturk
    Sena Ulu
    Ozkan Gungor
    International Urology and Nephrology, 2023, 55 : 1985 - 1994
  • [3] NETosis and kidney disease: what do we know?
    Alaygut, Demet
    Ozturk, Ilyas
    Ulu, Sena
    Gungor, Ozkan
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2023, 55 (08) : 1985 - 1994
  • [4] Glucose lowering and cardiovascular disease: what do we know and what should we do?
    Cheng, Alice Y. Y.
    Leiter, Lawrence A.
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2010, 17 : S25 - S31
  • [5] Nutritional Strategies to Prevent Muscle Loss and Sarcopenia in Chronic Kidney Disease: What Do We Currently Know?
    Massini, Giulia
    Caldiroli, Lara
    Molinari, Paolo
    Carminati, Francesca Maria Ida
    Castellano, Giuseppe
    Vettoretti, Simone
    NUTRIENTS, 2023, 15 (14)
  • [6] Sexual Dysfunction in Women With Cardiovascular Disease What Do We Know?
    Steinke, Elaine E.
    JOURNAL OF CARDIOVASCULAR NURSING, 2010, 25 (02) : 151 - 158
  • [7] Mediterranean Diet and Cardiovascular Disease Prevention: What Do We Know?
    Salas-Salvado, Jordi
    Becerra-Tomas, Nerea
    Francisco Garcia-Gavilan, Jesus
    Bullo, Monica
    Barrubes, Laura
    PROGRESS IN CARDIOVASCULAR DISEASES, 2018, 61 (01) : 62 - 67
  • [8] What do we know about apolipoprotein E and the prevention of cardiovascular disease?
    Tan, CE
    Tai, ES
    DRUG DEVELOPMENT RESEARCH, 2004, 62 (03) : 200 - 206
  • [9] Congenital Heart Disease and the Athlete What We Know and What We Do Not Know
    Dean, Peter N.
    Battle, Robert W.
    CARDIOLOGY CLINICS, 2016, 34 (04) : 579 - +
  • [10] COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know
    Dhawan, Rahul
    Gundry, Rebekah L.
    Brett-Major, David M.
    Mahr, Claudius
    Thiele, Geoffrey M.
    Lindsey, Merry L.
    Anderson, Daniel R.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2020, 144 : 12 - 14